Trevi Therapeutics Inc (TRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.89B
Last updated: Nov 17, 2026 at 4:20 PM ET
Trevi Therapeutics Inc (TRVI) Statistics
Trevi Therapeutics (TRVI) has a market cap of $1.89B and an enterprise value of $1.87B. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 10.08% from a year earlier.
Total Valuation
Enterprise value is 1.47% below the market cap, as cash exceeds debt.
| Market Cap | $1.89B |
|---|---|
| Enterprise Value | $1.87B |
| Latest price (Nov 17, 2026) | $13.51 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 18.82% over 52 weeks and trades 2.74% below its 50-day average.
| Beta (1Y) | 1.37 |
|---|---|
| 52-Week Change | +18.82% |
| 1-Month Change | +13.53% |
| 3-Month Change | -28.18% |
| 6-Month Change | +2.04% |
| 5-Year Change | +1054.04% |
| Total Return (1Y) | +18.82% |
| Total Return (3Y CAGR) | +113.37% |
| Total Return (5Y CAGR) | +67.39% |
| Return vs SPY (1Y) | +7.89% |
| Max Drawdown (1Y) | -39.08% |
| Max Drawdown (3Y) | -39.08% |
| Sharpe Ratio (1Y) | 0.30 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $13.89 |
| 200-Day Average | $14.55 |
| 52-Week Range | $9.82 to $20.22 |
| RSI (14 Days) | 47.6 |
| Average Volume (20 Days) | 1.62M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 38.86x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 38.86x |
|---|---|
| Quick Ratio | 38.86x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -20.07% over the last 12 months, against a 5-year average of -66.51%.
| Return on Equity (ROE) | -20.07% |
|---|---|
| Return on Assets (ROA) | -19.55% |
| ROE (5Y Average) | -66.51% |
| ROA (5Y Average) | -41.95% |
| ROIC (5Y Average) | -49.14% |
Scores
TRVI has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$31.00K |
| Operating Income | -$70.13M |
| Pretax Income | -$60.83M |
| Net Income | -$60.76M |
| Reported EPS (TTM) | -$0.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 97.41% of the $310.81M in total assets.
| Cash and Equivalents | $27.85M |
|---|---|
| Total Debt | $0 |
| Net Cash | $27.85M |
| Net Cash Per Share | $0.17 |
| Working Capital | $297.93M |
| Shareholder Equity | $302.76M |
| Book Value Per Share | $1.90 |
| Total Assets | $310.81M |
| Total Liabilities | $8.06M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $13.73M of capital spending, operating cash flow left -$75.16M of free cash flow.
| Operating Cash Flow | -$61.44M |
|---|---|
| Capital Expenditures | $13.73M |
| Free Cash Flow | -$75.16M |
| FCF Per Share | -$0.53 |
| Depreciation and Amortization | $2.56M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +23.20% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +23.20% |
Dividends and Yields
TRVI does not pay a dividend.
| Buyback Yield | 5.03% |
|---|---|
| Shareholder Yield | 5.03% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TRVI
What is TRVI's market cap?
Trevi Therapeutics has a market cap of $1.89B. Its enterprise value, which adds debt and subtracts cash, is $1.87B.
How many shares of TRVI are outstanding?
Trevi Therapeutics has 159.73M shares outstanding. The count is up 10.08% from a year earlier.
Does TRVI pay a dividend?
No. Trevi Therapeutics does not pay a dividend.
How much debt does TRVI have?
Trevi Therapeutics has $0 of total debt and $27.85M of cash and equivalents, a net cash position of $27.85M.
TRVI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors